Avacincaptad pegol
| Clinical data | |
|---|---|
| Trade names | Izervay |
| Other names | Zimura |
| License data | |
| Routes of administration | Intravitreal |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C395H453F21N142Na39O262P39 |
| Molar mass | 13885.245 g·mol−1 |
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration. Avacincaptad pegol is a complement inhibitor.
Avacincaptad pegol was approved for medical use in the United States in August 2023.